Stockreport

Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, non-Hodgkin's lymphoma, especially aggressive types like d [Read more]